{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T12:45:10Z","timestamp":1783514710560,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"InBrain Pharma"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1038\/s41591-024-03428-2","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T05:04:24Z","timestamp":1736226264000},"page":"819-828","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Intracerebroventricular anaerobic dopamine in Parkinson\u2019s disease with l-dopa-related complications: a phase 1\/2 randomized-controlled trial"],"prefix":"10.1038","volume":"31","author":[{"given":"Caroline","family":"Moreau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Odou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Labreuche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Demailly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Touzet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Reyns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6701-2888","authenticated-orcid":false,"given":"Bastien","family":"Gouges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Duhamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Barthelemy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Lannoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natacha","family":"Carta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Palas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mich\u00e8le","family":"Vasseur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Marchand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ollivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0824-7943","authenticated-orcid":false,"given":"C\u00e9line","family":"Leclercq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Potey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thavarak","family":"Ouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Baigne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Dujardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Carton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Sophie","family":"Rolland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Christophe","family":"Devedjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Foutel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Deplanque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Fisichella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2417-799X","authenticated-orcid":false,"given":"David","family":"Devos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,7]]},"reference":[{"key":"3428_CR1","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1056\/NEJM199810083391506","volume":"339","author":"AE Lang","year":"1998","unstructured":"Lang, A. E. & Lozano, A. M. Parkinson\u2019s disease. Two parts. N. Engl. J. Med. 339, 1044\u20131053 (1998).","journal-title":"N. Engl. J. Med."},{"key":"3428_CR2","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/ncpneuro0222","volume":"2","author":"CW Olanow","year":"2006","unstructured":"Olanow, C. W., Obeso, J. A. & Stocchi, F. Drug insight: continuous dopaminergic stimulation in the treatment of Parkinson\u2019s disease. Nat. Clin. Pract. Neurol. 2, 382\u2013392 (2006).","journal-title":"Nat. Clin. Pract. Neurol."},{"key":"3428_CR3","doi-asserted-by":"publisher","first-page":"IV37","DOI":"10.1007\/s00415-005-4008-5","volume":"252","author":"S Fahn","year":"2005","unstructured":"Fahn, S., Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinson\u2019s disease? J. Neurol. 252, IV37\u2013IV42 (2005).","journal-title":"J. Neurol."},{"key":"3428_CR4","doi-asserted-by":"publisher","first-page":"e0122708","DOI":"10.1371\/journal.pone.0122708","volume":"10","author":"A Ciesielska","year":"2015","unstructured":"Ciesielska, A., Sharma, N., Beyer, J., Forsayeth, J. & Bankiewicz, K. Carbidopa-based modulation of the functional effect of the AAV2-hAADC gene therapy in 6-OHDA lesioned rats. PLoS ONE 10, e0122708 (2015).","journal-title":"PLoS ONE"},{"key":"3428_CR5","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1111\/j.1468-1331.2011.03593.x","volume":"19","author":"O Gershanik","year":"2012","unstructured":"Gershanik, O. & Jenner, P. Moving from continuous dopaminergic stimulation to continuous drug delivery in the treatment of Parkinson\u2019s disease. Eur. J. Neurol. 19, 1502\u20131508 (2012).","journal-title":"Eur. J. Neurol."},{"key":"3428_CR6","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.parkreldis.2013.10.017","volume":"20","author":"D Devos","year":"2014","unstructured":"Devos, D. et al. Dopa-decarboxylase gene polymorphisms affect the motor response to L-dopa in Parkinson\u2019s disease. Parkinsonism Relat. Disord. 20, 170\u2013175 (2014).","journal-title":"Parkinsonism Relat. Disord."},{"key":"3428_CR7","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/mds.26078","volume":"30","author":"W Poewe","year":"2015","unstructured":"Poewe, W. & Antonini, A. Novel formulations and modes of delivery of levodopa. Mov. Disord. 30, 114\u2013120 (2015).","journal-title":"Mov. Disord."},{"key":"3428_CR8","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1097\/WCO.0000000000000354","volume":"29","author":"J Timpka","year":"2016","unstructured":"Timpka, J., Mundt-Petersen, U. & Odin, P. Continuous dopaminergic stimulation therapy for Parkinson\u2019s disease\u2014recent advances. Curr. Opin. Neurol. 29, 474\u2013479 (2016).","journal-title":"Curr. Opin. Neurol."},{"key":"3428_CR9","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.3233\/JPD-181476","volume":"8","author":"DJ van Wamelen","year":"2018","unstructured":"van Wamelen, D. J., Grigoriou, S., Chaudhuri, K. R. & Odin, P. Continuous drug delivery aiming continuous dopaminergic stimulation in Parkinson\u2019s disease. J. Parkinsons Dis. 8, S65\u2013S72 (2018).","journal-title":"J. Parkinsons Dis."},{"key":"3428_CR10","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3233\/JPD-230372","volume":"14","author":"A Demailly","year":"2024","unstructured":"Demailly, A., Moreau, C. & Devos, D. Effectiveness of continuous dopaminergic therapies in Parkinson\u2019s disease: a review of l-DOPA pharmacokinetics\/pharmacodynamics. J. Parkinsons Dis. 14, 925\u2013939 (2024).","journal-title":"J. Parkinsons Dis."},{"key":"3428_CR11","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S1474-4422(18)30239-4","volume":"17","author":"R Katzenschlager","year":"2018","unstructured":"Katzenschlager, R. et al. Apomorphine subcutaneous infusion in patients with Parkinson\u2019s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 17, 749\u2013759 (2018).","journal-title":"Lancet Neurol."},{"key":"3428_CR12","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","volume":"13","author":"CW Olanow","year":"2014","unstructured":"Olanow, C. W. et al. Continuous intrajejunal infusion of levodopa\u2013carbidopa intestinal gel for patients with advanced Parkinson\u2019s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 13, 141\u2013149 (2014).","journal-title":"Lancet Neurol."},{"key":"3428_CR13","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/S1474-4422(22)00400-8","volume":"21","author":"MJ Soileau","year":"2022","unstructured":"Soileau, M. J. et al. Safety and efficacy of continuous subcutaneous foslevodopa\u2013foscarbidopa in patients with advanced Parkinson\u2019s disease: a randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol. 21, 1099\u20131109 (2022).","journal-title":"Lancet Neurol."},{"key":"3428_CR14","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1007\/s00415-014-7254-6","volume":"261","author":"L Perestelo-P\u00e9rez","year":"2014","unstructured":"Perestelo-P\u00e9rez, L. et al. Deep brain stimulation in Parkinson\u2019s disease: meta-analysis of randomized controlled trials. J. Neurol. 261, 2051\u20132060 (2014).","journal-title":"J. Neurol."},{"key":"3428_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-019-1276-8","volume":"19","author":"A Fasano","year":"2019","unstructured":"Fasano, A. et al. Characterizing advanced Parkinson\u2019s disease: OBSERVE-PD observational study results of 2615 patients. BMC Neurol. 19, 50 (2019).","journal-title":"BMC Neurol."},{"key":"3428_CR16","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/mds.870020302","volume":"2","author":"JG De Yebenes","year":"1987","unstructured":"De Yebenes, J. G. et al. Continuous intracerebroventricular infusion of dopamine and dopamine agonists through a totally implanted drug delivery system in animal models of Parkinson\u2019s disease. Mov. Disord. 2, 143\u2013158 (1987).","journal-title":"Mov. Disord."},{"key":"3428_CR17","first-page":"62","volume":"47","author":"N Venna","year":"1984","unstructured":"Venna, N., Sabin, T. D., Ordia, J. I. & Mark, V. H. Treatment of severe Parkinson\u2019s disease by intraventricular injection of dopamine. Appl. Neurophysiol. 47, 62\u201364 (1984).","journal-title":"Appl. Neurophysiol."},{"key":"3428_CR18","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/ana.410260620","volume":"26","author":"MK Horne","year":"1989","unstructured":"Horne, M. K. et al. Intraventricular infusion of dopamine in Parkinson\u2019s disease. Ann. Neurol. 26, 792\u2013794 (1989).","journal-title":"Ann. Neurol."},{"key":"3428_CR19","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.nbd.2017.03.013","volume":"103","author":"C Laloux","year":"2017","unstructured":"Laloux, C. et al. Continuous cerebroventricular administration of dopamine: a new treatment for severe dyskinesia in Parkinson\u2019s disease? Neurobiol. Dis. 103, 24\u201331 (2017).","journal-title":"Neurobiol. Dis."},{"key":"3428_CR20","doi-asserted-by":"publisher","first-page":"104846","DOI":"10.1016\/j.nbd.2020.104846","volume":"139","author":"C Moreau","year":"2020","unstructured":"Moreau, C. et al. Intraventricular dopamine infusion alleviates motor symptoms in a primate model of Parkinson\u2019s disease. Neurobiol. Dis. 139, 104846 (2020).","journal-title":"Neurobiol. Dis."},{"key":"3428_CR21","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s13534-022-00226-y","volume":"12","author":"A Malvea","year":"2022","unstructured":"Malvea, A., Babaei, F., Boulay, C., Sachs, A. & Park, J. Deep brain stimulation for Parkinson\u2019s disease: a review and future outlook. Biomed. Eng. Lett. 12, 303\u2013316 (2022).","journal-title":"Biomed. Eng. Lett."},{"key":"3428_CR22","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov. Disord. 30, 1591\u20131601 (2015).","journal-title":"Mov. Disord."},{"key":"3428_CR23","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12984-021-00905-4","volume":"18","author":"H Khodakarami","year":"2021","unstructured":"Khodakarami, H., Shokouhi, N. & Horne, M. A method for measuring time spent in bradykinesia and dyskinesia in people with Parkinson\u2019s disease using an ambulatory monitor. J. Neuroeng. Rehabil. 18, 116 (2021).","journal-title":"J. Neuroeng. Rehabil."},{"key":"3428_CR24","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz, C. G. et al. Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Movement Disorder Society UPDRS Revision Task Force. Mov. Disord. 23, 2129\u20132170 (2008).","journal-title":"Mov. Disord."},{"key":"3428_CR25","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","volume":"14","author":"MW Johns","year":"1991","unstructured":"Johns, M. W. A new method for measuring daytime sleepiness: the Epworth sleepiness. Sleep 14, 540\u2013545 (1991).","journal-title":"Sleep"},{"key":"3428_CR26","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/mds.23476","volume":"26","author":"C Trenkwalder","year":"2011","unstructured":"Trenkwalder, C. et al. Parkinson\u2019s disease sleep scale\u2014validation of the revised version PDSS-2. Mov. Disord. 26, 644\u2013652 (2011).","journal-title":"Mov. Disord."},{"key":"3428_CR27","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine, Z. S. et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J. Am. Geriatr. Soc. 53, 695\u2013699 (2005).","journal-title":"J. Am. Geriatr. Soc."},{"key":"3428_CR28","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1017\/S1041610210000876","volume":"22","author":"K de Medeiros","year":"2010","unstructured":"de Medeiros, K. et al. The Neuropsychiatric Inventory-Clinician rating scale (NPI-C): reliability and validity of a revised assessment of neuropsychiatric symptoms in dementia. Int. Psychogeriatr. 22, 984\u2013994 (2010).","journal-title":"Int. Psychogeriatr."},{"key":"3428_CR29","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1002\/mds.25919","volume":"29","author":"AF Leentjens","year":"2014","unstructured":"Leentjens, A. F. et al. The Parkinson Anxiety Scale (PAS): development and validation of a new anxiety scale. Mov. Disord. 29, 1035\u20131043 (2014).","journal-title":"Mov. Disord."},{"key":"3428_CR30","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1136\/jnnp.2005.075929","volume":"77","author":"P Sockeel","year":"2006","unstructured":"Sockeel, P. et al. The Lille apathy rating scale (LARS), a new instrument for detecting and quantifying apathy: validation in Parkinson\u2019s disease. J. Neurol. Neurosurg. Psychiatry 77, 579\u2013584 (2006).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"3428_CR31","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.neurol.2009.06.003","volume":"165","author":"C Ardouin","year":"2009","unstructured":"Ardouin, C. et al. Assessment of hyper- and hypodopaminergic behaviors in Parkinson\u2019s disease [in French]. Rev. Neurol. 165, 845\u2013856 (2009).","journal-title":"Rev. Neurol."},{"key":"3428_CR32","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3102\/10769986006002107","volume":"6","author":"LV Hedges","year":"1981","unstructured":"Hedges, L. V. Distribution theory for Glass\u2019s estimator of effect size and related estimators. J. Educ. Stat. 6, 107\u2013128 (1981).","journal-title":"J. Educ. Stat."},{"key":"3428_CR33","doi-asserted-by":"publisher","first-page":"51","DOI":"10.20982\/tqmp.17.1.p051","volume":"17","author":"D Cousineau","year":"2021","unstructured":"Cousineau, D. & Goulet-Pelletier, J. C. A study of confidence intervals for Cohen\u2019s dp in within-subject designs with new proposals. Quant. Methods Psychol. 17, 51\u201375 (2021).","journal-title":"Quant. Methods Psychol."},{"key":"3428_CR34","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1037\/0033-2909.112.1.155","volume":"112","author":"J Cohen","year":"1992","unstructured":"Cohen, J. A power primer. Psychol. Bull. 112, 155\u2013159 (1992).","journal-title":"Psychol. Bull."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03428-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03428-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03428-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T08:26:23Z","timestamp":1742372783000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03428-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,7]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["3428"],"URL":"https:\/\/doi.org\/10.1038\/s41591-024-03428-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4654361\/v1","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,7]]},"assertion":[{"value":"28 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.D., C.M., J.C.D. and M.F. have an equity stake in InBrain Pharma. A.D. and M.F. are employees of InBrain Pharma. C.M. has received grants from the France Parkinson charity and honoraria from Orkyn, Apopharma and Boston Scientific for consultancy and lectures on Parkinson\u2019s disease at symposia. C.M. is CMO of Feetme and holds stakes in InBrain Pharma and InVenis Biotherapies. P.O. is the director of the pharmaceutical department of the University Hospital of Lille and leads the research group on injectable forms and associated technologies. As such, P.O. has signed contracts with many pharmaceutical companies. All contracts are signed by delegations from the University of Lille or CHU Lille. There are no personal contracts. D.D. has received PHRC grants from the French Ministry of Health (PHRC and ANR), European grants (H2020 and Coen) and research funding from the ARSLA charity, France; Parkinson charity; Fondation Credit Agricole, and Fondation de France. He has served on advisory boards, served as a consultant and given lectures for pharmaceutical companies such as Abbvie, Alterity, Orkyn, Air Liquide, Elivie, Homeperf, Apopharma, Lundbeck, Everpharma, Medtronic, Boston Scientific, Everpharma, UCB Pharma, EISAI, Servier, PTC Therapeutics, Orion, AB Science, Alzprotect, Cajal Neuroscience and Cure Parkinson Trust. He holds stakes in InBrain Pharma and InVenis Biotherapies. G.T., N.R., C.B., D.L., N.C., B.P., F.M., B.G., K.D., L.C., A.S.R., D.D. and J.C.D. have nothing to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}